Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.

Simple item page
dc.contributor.authorKane, Michael P
dc.contributor.authorBriceland, Laurie L
dc.contributor.authorGarris, R E
dc.contributor.authorFavreau, B N
dc.date.accessioned2023-11-21T20:17:13Z
dc.date.available2023-11-21T20:17:13Z
dc.date.issued1990-09
dc.descriptionClick on the Resource Link to access the article (may not be free).
dc.description.abstractThe effect of drug-use review on concomitant histamine H2-receptor antagonist-sucralfate therapy at a 600-bed, university-affiliated Veterans Affairs medical center was studied. In an effort to curtail the concomitant use of H2-antagonist plus sucralfate therapy, the department of pharmacy, in conjunction with the gastroenterology service, developed and introduced criteria for the appropriate use of combination therapy. The extent of prescribing of concomitant histamine H2-receptor antagonist-sucralfate therapy before and after implementation of criteria-based guidelines and the appropriateness of current H2-receptor antagonist-sucralfate combination therapy, based on the guidelines, were assessed. The effectiveness of the intervention process was evaluated, and cost savings associated with intervention were calculated. After intervention, the number of treatment courses of histamine H2-receptor antagonist-sucralfate combination therapy decreased by 30%. However, of the 109 evaluable postintervention combination treatment courses, only one complied with both the indication and the duration of treatment criteria. This review of prescribing patterns and the implementation of criteria-based guidelines proved an effective means of reducing inappropriate combination therapy and resulted in annual cost savings of $25,000.
dc.description.urihttps://doi.org/10.1093/ajhp/47.9.2007
dc.identifier.citationKane MP, Briceland LL, Garris RE, Favreau BN. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy. Am J Hosp Pharm. 1990 Sep;47(9):2007-10. PMID: 1977317.
dc.identifier.issn0002-9289
dc.identifier.other1977317
dc.identifier.urihttps://hdl.handle.net/20.500.14303/362
dc.language.isoen
dc.publisherAmerican Society Of Hospital Pharmacists
dc.relation.ispartofAmerican Journal of Hospital Pharmacy
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectCosts and Cost Analysis
dc.subjectDrug Therapy, Combination
dc.subjectDrug Utilization
dc.subjectHistamine H2 Antagonists/administration & dosage/therapeutic use
dc.subjectPharmacy Service, Hospital/organization & administration
dc.subjectSucralfate/administration & dosage/therapeutic use
dc.subjectUtilization Review
dc.titleDrug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Kane, Michael Publications
Briceland, Laurie Publications